Latest Share Chat

REMOVE ADS

Hutchmed Share News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes

Get Live Data

168.00 3.25 (1.97%)

Bid:

158.50

Ask:

167.50

Spread: 9.00 (5.678%)

Market Cap: £1.44b

Last checked at -

Intraday Hutchmed Share Chart

REMOVE ADS

Hutchmed News

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib t...

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquinti...

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director...

Hutchmed reports progress on two oncology fronts

(Sharecast News) - Hutchmed China reported significant strides in oncology research on Tuesday, completing patient enrollment for a bridging study of ...

IN BRIEF: Hutchmed China finalises patient enrolment for Tazemetostat

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Completes patient enrolment for bridging phase ...

Hutchmed tumour therapy candidate gets breakthrough designation

(Sharecast News) - Pharmaceuticals developer Hutchmed China announced on Tuesday that the Center for Drug Evaluation of China's National Medical Produ...

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in Chin...

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.